Gynaecologic cancers
1 trial- 2018SOLO-1BRCA-mutated ovarianIn 391 patients with newly diagnosed BRCA1/2-mutated advanced ovarian cancer in response to first-line platinum, maintenance olaparib for two years improved progression-free and overall survival compared with placebo.